Clinchoice Raises $150M In Series E Round Led By China's Legend Capital
06/07/22, 12:00 AM
Location
philadelphiaMoney raised
$150 million
Round Type
series e
ClinChoice, a Sino-US contract research organisation (CRO), has raised $150 million in as Series E funding round led by Legend Capital, the fund management arm of Chinese conglomerate Legend Holdings, according to a report by DealStreetAsia.
Company Info
Location
philadelphia, pennsylvania, united states
Additional Info
ClinChoice is a global clinical CRO, providing high-quality Integrated One-stop Service Offerings for new bio-pharmaceutical and medical device clients worldwide. Our Service Offerings cover Clinical Operation, Project Management, Biostatistics, Data Management, Biostatistical Programming, Regulatory Affairs, Medical Affairs, Feasibility Research, HGRAC Submission, Clinical Safety Management, Site Management Organization, Nature Medicine/Traditional Chinese Medicine and Phase I Clinical Research, etc. Now, ClinChoice has over 3,000 employees worldwide covering most of drug development hotbeds in US, China, multiple countries in Europe and Southeast Asia. Since its inception, ClinChoice has completed multiple rounds of financing, with investments from renowned institutional investors including Goldman Sachs, Lilly Asia Ventures, and DFJ Dragon Fund.